# Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

> **NCT04480554** · PHASE2 · TERMINATED · sponsor: **University of Pennsylvania** · enrollment: 78 (actual)

## Conditions studied

- Opioid-use Disorder
- HIV-1-infection
- Immune Activation
- Inflammation
- Methadone
- Buprenorphine
- Naltrexone
- Antiretroviral Treatment

## Interventions

- **DRUG:** Methadone
- **DRUG:** Buprenorphine/naloxone
- **DRUG:** XR-Naltrexone

## Key facts

- **NCT ID:** NCT04480554
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-30
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** Funding not renewed
- **Last updated:** 2026-04-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04480554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04480554, "Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04480554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*